Background Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can
result in durable responses in patients with melanoma who have progressed after …

Objectives: Treatment of locally advanced unresectable or metastatic cutaneous squamous
cell carcinoma (mCSCC) is suboptimal with a paucity of robust data on systemic therapy …

Background No systemic therapies have been approved for the treatment of advanced
cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy …

Background Brain metastases are a common cause of disabling neurologic complications
and death in patients with metastatic melanoma. Previous studies of nivolumab combined …

Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-
particles (cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or …

Background In a pilot study involving patients with cutaneous squamous-cell carcinoma, a
high percentage of patients had a pathological complete response with the use of two doses …

Importance Ipilimumab and other immune therapies are effective treatment options for
patients with advanced melanoma but cause frequent immune-related toxic effects …

Background Combination nivolumab plus ipilimumab was efficacious in patients with
asymptomatic melanoma brain metastases (MBM) in CheckMate 204, but showed low …

Summary Background Previously, findings from CheckMate 238, a double-blind, phase 3
adjuvant trial in patients with resected stage IIIB–C or stage IV melanoma, showed …

Upper gastrointestinal tumors involving the esophagus and the stomach are a serious public
health problem worldwide. The West has seen a dramatic increase in the incidence of …